cilengitide
Trials 29
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 35 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cilengitide | “Subjects will receive cilengitide monotherapy for 2 weeks (Weeks 1 and 2); thereafter, cilengitide will be given in combination with the standard treatment regimen during Weeks 3 to 36.” NCT01558687 ↗ |
| Known as | Cil | “Cilengitide (Cil) will be administered at a dose of 1000 milligram (mg) as intravenous infusion twice weekly over 1 hour on Days 1 and 4.” NCT00842712 ↗ |
| Known as | Cilengitida | ChEMBL registry synonym — accepted as the source's own label CHEMBL429876 ↗ |
| Known as | EMD 121974 | “A Multi-center, Open-label, Randomized, Controlled Phase I Trial to Investigate the Effects of Cilengitide (EMD 121974) Using Dynamic MR and FET-PET Imaging as a...” NCT01558687 ↗6“This multi-institutional phase I trial was designed to determine the maximum-tolerated dose (MTD) of cilengitide (EMD 121974) and to evaluate the use of perfusion magnetic...” PMID 17470857 ↗ May 2007 “Cilengitide (EMD121974) in Combination With Whole Brain Radiotherapy in Patients With Brain Metastases From Lung Cancer” NCT00884598 ↗ “Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma” NCT00679354 ↗ “Cilengitide (EMD121974; Merck KgaA, Darmstadt, Germany), a cyclic pentapeptide containing the sequence RGD” NCT01165333 ↗ “Cilengitide (EMD 121974) may stop the growth of cancer cells by stopping blood flow to the cancer” NCT00077155 ↗ “Patients receive cilengitide (EMD 121974) IV over 1 hour twice weekly.” NCT00063973 ↗ |
| Known as | EMD-12192 | ChEMBL registry synonym — accepted as the source's own label CHEMBL429876 ↗ |
| Known as | NSC 707544 | “Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735.” PMID 21049281 ↗ Nov 20101“A Phase 2 Study of EMD 121974 (Cilengitide, NSC 707544) in Patients With Metastatic Melanoma” NCT00082875 ↗ |
| Action | Inhibit | “Cilengitide is a selective integrin inhibitor that is well tolerated and has demonstrated biologic activity in patients with recurrent malignant glioma.” PMID 22517399 ↗ Apr 2012 |
| Modality | Peptide | “Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.” PMID 18981465 ↗ Nov 2008 |
| Route | Intravenous | “administered as a twice weekly intravenous infusion” PMID 17470857 ↗ May 2007 |